|
Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb; Roche |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Amgen |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Expert Testimony - Bristol-Myers Squibb; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Travel, Accommodations, Expenses - Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche |